Author + information
- Received June 6, 2006
- Revision received August 24, 2006
- Accepted August 28, 2006
- Published online December 19, 2006.
- Matthias Pfisterer, MD, FACC⁎,⁎ (, )
- Hans Peter Brunner-La Rocca, MD⁎,
- Peter T. Buser, MD, FACC⁎,
- Peter Rickenbacher, MD§,
- Patrick Hunziker, MD†,
- Christian Mueller, MD‡,
- Raban Jeger, MD⁎,
- Franziska Bader, RN⁎,
- Stefan Osswald, MD, FACC⁎,
- Christoph Kaiser, MD⁎,
- BASKET-LATE Investigators
- ↵⁎Reprint requests and correspondence:
Dr. Matthias Pfisterer, Professor of Cardiology, Head Department of Cardiology, University Hospital, CH-4031 Basel, Switzerland.
Objectives We sought to define the incidence of late clinical events and late stent thrombosis in patients treated with drug-eluting (DES) versus bare-metal stents (BMS) after the discontinuation of clopidogrel as well as their timing and outcome.
Background There is growing concern that delayed endothelialization after DES implantation may lead to late stent thrombosis and related myocardial infarction (MI) or death. However, event rates and outcomes after clopidogrel discontinuation versus BMS are unknown.
Methods A consecutive series of 746 nonselected patients with 1,133 stented lesions surviving 6 months without major events were followed for 1 year after the discontinuation of clopidogrel. Patients were assigned randomly 2:1 to DES versus BMS in BASKET (Basel Stent Kosten Effektivitäts Trial). The primary focus of this observation was cardiac death/MI.
Results Rates of 18-month cardiac death/MI were not different between DES and BMS patients. However, after the discontinuation of clopidogrel (between months 7 and 18), these events occurred in 4.9% after DES versus 1.3% after BMS implantation. Target vessel revascularization remained lower after DES, resulting in similar rates of all clinical events for this time period (DES 9.3%, BMS 7.9%). Documented late stent thrombosis and related death/target vessel MI were twice as frequent after DES versus BMS (2.6% vs. 1.3%). Thrombosis-related events occurred between 15 and 362 days after the discontinuation of clopidogrel, presenting as MI or death in 88%.
Conclusions After the discontinuation of clopidogrel, the benefit of DES in reducing target vessel revascularization is maintained but has to be balanced against an increase in late cardiac death or nonfatal MI, possibly related to late stent thrombosis.
The BAsel Stent Kosten-Effektivitäts Trial-LAte Thrombotic Events (BASKET-LATE) Investigators are listed in the Appendix.
This study was supported by the Basel Cardiac Research Foundation, Basel, Switzerland, and the University Hospital, Basel, Switzerland. They had no role in the design and conduct of the study, collection, management, analysis, or interpretation of the data. There was no industry sponsor for this study.
- Received June 6, 2006.
- Revision received August 24, 2006.
- Accepted August 28, 2006.
- American College of Cardiology Foundation